Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Supportive Care in Cancer

• Publication date

  2017-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00520-016-3560-0PMID 28074289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

  2016cited by this paper
• Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: A systematic review.

  2016cited by this paper
• Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

  2016cited by this paper
• Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.

  2015cited by this paper
• An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin

  2015cited by this paper
• Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options

  2015cited by this paper
• Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.

  2015cited by this paper
• Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC

  2015cited by this paper
• Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

  2014cited by this paper
• Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force.

  2014cited by this paper
• Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model

  2013cited by this paper
• The role of ghrelin in anorexia-cachexia syndromes.

  2013cited by this paper
• Multitargeted treatment of cancer cachexia.

  2012cited by this paper
• Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

  2012cited by this paper
• The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats.

  2011cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011cited by this paper
• Cachexia as a major underestimated and unmet medical need: facts and numbers

  2010cited by this paper
• Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.

  2009cited by this paper
• Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats.

  2007cited by this paper
• Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning

  2007cited by this paper
• Symptom prevalence in patients with incurable cancer: a systematic review.

  2007cited by this paper
• Role of Corticosteroids in Palliative Care

  2007cited by this paper
• Grip strength, body composition, and mortality.

  2007cited by this paper
• Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

  2007cited by this paper
• Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia.

  2006cited by this paper
• Therapeutic action of ghrelin in a mouse model of colitis.

  2006cited by this paper
• Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

  2004cited by this paper
• Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells.

  2002cited by this paper
• Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management

  2002cited by this paper
• Thalidomide Suppresses the Interleukin 1β‐Induced NFκB Signaling Pathway in Colon Cancer Cells

  2002cited by this paper
• Thalidomide Suppresses the Interleukin 1β-Induced NFκB Signaling Pathway in Colon Cancer Cells

  2002cited by this paper
• Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity*

  2001cited by this paper
• Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.

  2001cited by this paper
• Validation of the Edmonton Symptom Assessment Scale

  2000cited by this paper
• Ghrelin strongly stimulates growth hormone release in humans.

  2000cited by this paper

• Endocrinological aspects of sarcopenic obesity

  2026cites this paper
• Glucocorticoid-induced muscle weakness in ECOPD: a perspective on mechanisms and emerging pharmacological interventions.

  2026cites this paper
• Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study

  2025cites this paper
• Ovarian cancer and malnutrition: a literature review

  2025cites this paper
• Ghrelin and LEAP2: Subtle Players in Cachexia, Essential for the Bigger Picture.

  2025cites this paper
• Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions

  2025cites this paper
• SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)

  2024cites this paper
• Sarcopenic obesity: a review

  2024cites this paper
• Combination therapy of corylifol A and anamorelin attenuates cachexia by decreasing pro-inflammatory cytokines, inhibiting lipolysis and increasing food intake in a murine colon cancer model

  2024cites this paper
• Advancing cancer cachexia diagnosis with -omics technology and exercise as molecular medicine

  2024cites this paper
• The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors

  2023cites this paper
• The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis

  2023cites this paper
• Updates in Cancer-Related Symptom Management of Anorexia and Cachexia Syndrome.

  2022cites this paper
• Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: Synergy among nutritional supplementation, pharmacotherapy, and rehabilitation.

  2021cites this paper
• Therapeutic effects of androgens for cachexia.

  2021cites this paper
• Role of Complementary and Alternative Medicine in the Management of Cancer Cachexia

  2021cites this paper
• Drugs for the Treatment of Muscle Atrophy

  2021cites this paper
• Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.

  2021cites this paper
• Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment.

  2021cites this paper
• Management of Cancer Cachexia: ASCO Guideline.

  2020cites this paper
• Recent Advances of Sarcopenia and Frailty in CKD

  2020cites this paper
• Pharmacological Intervention for Sarcopenia in Chronic Kidney Disease

  2020cites this paper
• Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery

  2020cites this paper
• Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model

  2020influential citation
• Cachexia and anorexia in cancer; a systematic review

  2020cites this paper
• Pancreatic cancer: Best supportive care.

  2019cites this paper
• Anabolic and Anticatabolic Agents in Burns

  2019cites this paper
• Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis

  2019cites this paper
• Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer

  2019cites this paper
• Effect of progressive sarcopenia during postoperative 6 months on long-term prognosis of completely resected lung cancer.

  2019cites this paper
• Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review

  2019cites this paper
• Der mangelernährte Patient auf der Intensivstation

  2018cites this paper
• Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials

  2018cites this paper
• Drugs of Muscle Wasting and Their Therapeutic Targets.

  2018cites this paper
• Inter-tissue communication in cancer cachexia

  2018cites this paper
• The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews

  2018cites this paper
• Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies

  2018cites this paper
• Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

  2018cites this paper
• The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

  2018cites this paper
• Advances in the diagnosis and treatment of patients with cancer cachexia

  2018cites this paper
• Palliativmedizin: Grundlagen und Symptommanagement

  2017cites this paper
• Oncology Update: Anamorelin

  2017cites this paper
• THE GHRELIN SYSTEM; BEYOND THE ROLE IN ENERGY HOMEOSTASIS

  2017cites this paper
• Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy.

  2017cites this paper
• He-Wei granules inhibit chemotherapy-induced vomiting (CINV) in rats by reducing oxidative stress and regulating 5-HT, substance P, ghrelin and obestatin

  2017cites this paper
• Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia

  2017cites this paper
• Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

  2017cites this paper
• The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.

  2017cites this paper
• Ghrelin for the management of cachexia associated with cancer.

  2016cites this paper